Business & Finance

Novartis in the lead to acquire cancer drug developer MorphoSys

06 February 2024, 9:40 pm 1 minute

Reuters exclusively reported that drug maker Novartis AG (NOVN.S) is in advanced talks to acquire MorphoSys AG (MORG.DE), a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion).

Market Impact

MorphoSys shares rose more than 40% on the news.

Article Tags

Topics of Interest: Business & Finance

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Europe

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Share this article

Work Email Address *

Country *

I'd like to receive communications about Reuters resources, events, products, or services.

(Please note you can manage and update your preferences at any time.) By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement.

By submitting your details, you are agreeing to receive communications about Reuters resources, events, products, or services. By submitting your details, you are also acknowledging that you have read and understood our: Privacy Statement. * required field

Work Email Address *

Country *

More of Reuters Best

How bond vigilantes could check Trump’s power

Novartis in the lead to acquire cancer drug developer MorphoSys

Market Impact

More of Reuters Best

How bond vigilantes could check Trump’s power

Meta warns India antitrust ruling could force roll back of features, hurt business

Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast

Barrick to suspend operations in Mali after gold seized